Kestra Medical Technologies Prices Upsized Public Offering of 6M Shares at $23 Each
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Newsfilter
- Upsized Offering: Kestra Medical Technologies has priced its public offering of 6 million common shares at $23 each, expecting gross proceeds of $138 million, which will significantly bolster its operational and R&D funding.
- Underwriter Selection: The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs, and Wells Fargo, reflecting strong market confidence and support for Kestra's growth prospects.
- Additional Share Option: Kestra has granted underwriters a 30-day option to purchase an additional 900,000 shares at the public offering price, enhancing fundraising flexibility and potential revenue.
- Closing Timeline: The offering is expected to close on December 4, 2025, which, if successful, will provide timely financial support for the company's expansion in the medical device sector.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMTS is 30.00 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.980
Low
28.00
Averages
30.00
High
32.00
Current: 22.980
Low
28.00
Averages
30.00
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
